News and Trends 20 Dec 2022
Verona Pharma drug meets COPD phase 3 trial endpoints
Verona Pharma plc has announced positive results of its phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment…
Verona Pharma
- Latest Posts
News and Trends 18 Oct 2022
Progress of COPD drug boosted by debt financing of up to $150M
Verona Pharma plc has today (October 17) announced that it has entered into a debt financing facility providing access of…
News and Trends 17 Oct 2022
More positive news announced for Verona’s COPD treatment
Clinical-stage biopharmaceutical company, Verona, has announced more positive news from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats…
News and Trends 19 Aug 2022
Nuance Pharma receives clearance to begin clinical trials with Ensifentrine in China
Nuance Pharma and its partner Verona Pharma plc have received clearance from the Center of Drug Evaluation for the investigational…
ADVERTISEMENT
More News! 5 Aug 2019
Phase II Promise for Inhaled Chronic Lung Disease Treatment
A first-in-class inhaled drug developed by the UK biotech Verona Pharma improved lung function in a phase II trial treating…
More News! 14 Jan 2019
Inhaled Lung Disease Treatment Encounters Mixed Results in Phase II Trial
An inhaled drug from British company Verona Pharma has failed to significantly improve lung function in patients with the lung…
Interview 20 Jun 2018
“Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech
Some careers take on an international scope and span the breadth of big players in the pharmaceutical industry and small…
News and Trends 7 Sep 2017
Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug
A study of Verona's combination therapy for COPD observed a clinical improvement in lung function and faster onset-of-action. Verona filed…
News and Trends 26 Jul 2017
Update: Potential Breakthrough Treatment for Deadly Lung Disease Starts Phase IIb
Update (26/07/2017): Verona Pharma has dosed the first patients in the PhaseIIb with RPL554 in patients with chronic obstructive pulmonary disease…
News and Trends 19 Apr 2017
UPDATE: Verona sets terms & dials back its IPO goal to a still-hefty €75M
UPDATE: Verona set the terms for its US IPO yesterday and knocked $10M (€9.3M) off its target, now shooting for $75M (€70M). …